Brought to you by 
Chattem buys J&J, Pfizer OTC drugs for $410mm
05 Dec 2022
Executive Summary
In order to proceed with its $16.6bn acquisition of Pfizer's Consumer Health Care Group, Johnson & Johnson has agreed to sell Chattem (markets branded OTC medical products, toiletries, and dietary supplements) the US rights to its Act mouthwash and Balmex diaper cream. Chattem is also getting US rights to three Pfizer OTC products: Cortizone topical analgesic, Kaopectate anti-diarrheal, and the Unisom sleep aid. Chattem has agreed to pay $410mm in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chattem buys J&J, Pfizer OTC drugs for $410mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice